EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors

News provided by

EUSA Pharma

21 Apr, 2015, 04:00 ET

HEMEL HEMPSTEAD, England, April 21, 2015 /PRNewswire/ --

EUSA Pharma (EUSA), a recently-established profitable specialty pharmaceutical company with global reach, today announced the appointment of Lee Morley as Chief Executive Officer, and Dr Göran Ando as a Non-Executive Director.  Bryan Morton, who established EUSA Pharma as founder and first CEO, will become Executive Chairman.  

Lee Morley joins from Jazz Pharmaceuticals plc (Jazz), where he was Vice President, Head of Commercial for Europe and International Markets.  At Jazz, he had responsibility for the original EUSA Pharma business following its acquisition in 2012, until the recent launch of EUSA as a newly-established independent company with a portfolio of specialty hospital products, multi-national commercial infrastructure and the EUSA Pharma brand name, which were acquired from Jazz in March 2015.  

Lee brings to EUSA extensive commercial experience gained over 20 years in the pharmaceutical industry.  Previously, he held several senior commercial positions at EUSA Pharma, prior to its acquisition by Jazz, including Regional Vice President, and was Director of Sales Effectiveness at the specialty oncology and critical care company Zeneus Pharma.  He also held a number of management positions in sales and marketing at Merck, Sharp and Dohme (MSD), including UK National Sales Manager.  He began his industry career at MSD as a Medical Representative, following his graduation from Kings College London with a degree in chemistry.

Dr Göran Ando is Senior Advisor with EUSA Pharma's lead shareholder, Essex Woodlands.  He has over 35 years' experience of the pharmaceutical industry, spent in a variety of senior international roles.  He is currently Chairman of Novo Nordisk, the world's leading pharmaceutical company focused on diabetes.  He is also Chairman of Symphogen, and sits on the Board of Directors at Molecular Partners.  Previously, he was CEO of Celltech Group plc prior to its acquisition by UCB Pharma, and was Head of R&D at Pharmacia / Pharmacia & Upjohn. Dr Ando holds a Bachelor of Arts degree from Uppsala University in Sweden and a Medical Degree from Linkoeping University (Sweden).

"We are delighted to welcome both Lee and Göran to EUSA Pharma during this exciting time in the development of the company," said Bryan Morton, EUSA Pharma's Executive Chairman.  "We have highly ambitious growth plans to build EUSA into a world-class specialty pharma business through acquisition and in-licensing, and Lee's extensive commercial experience will prove invaluable in helping us achieve our goal.  We also welcome the strategic insight and direction Göran will provide as we transform the business, and the ongoing strong support of Essex Woodlands."  

"I am delighted to join EUSA, and to lead this ambitious company as we transform our specialty business into a true leader in the field," said Lee Morley, EUSA Pharma's Chief Executive.  "Having worked with the EUSA team for many years previously, I am confident we have the infrastructure in place to support our rapid growth, as we become a highly attractive partner for companies seeking specialist transatlantic commercialization expertise."  

"I am honored to join EUSA, and look forward to helping the team build a remarkable new business," said Dr Göran Ando, Senior Advisor, Essex Woodlands.  "Having worked closely with Bryan supporting the rapid growth of the original EUSA Pharma, both myself and Essex are delighted to contribute to this successful new venture."  

About EUSA Pharma 

Founded in March 2015, EUSA Pharma is a profitable specialty pharmaceutical company.  The company has commercial operations in the US and Europe, and a wider distribution network in approximately 40 countries around the world.  Currently, EUSA has a portfolio of five approved and several named-patient specialty hospital products, and the company has ambitious plans to expand this through acquisition and in-licensing.  EUSA is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies, and is supported by significant funding raised from leading life science investor Essex Woodlands.  

EUSA Pharma's products include: Caphosol® for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy; Collatamp®, a surgical implant impregnated with the antibiotic gentamicin for the treatment and prevention of post-surgical acquired infection; Custodiol® solution for use in the preservation of organs for transplantation; Fomepizole® for the treatment of ethylene glycol poisoning; and Xenazine® for the treatment of movement disorders associated with Huntington's chorea.

For more information please visit http://www.eusapharma.com.

Contacts
Bryan Morton
Executive Chairman
EUSA Pharma
Tel: +44(0)330-5001140

Rob Budge
RJB Communications
Tel: +44(0)1865-760969
Mobile: +44(0)7710-741241

SOURCE EUSA Pharma

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.